Nivolumab plus chemotherapy demonstrates significant overall survival (OS) benefit vs chemotherapy in first-line treatment of gastric and oesophageal cancers

Results from phase 3 CheckMate -649 trial showed longer median OS (HR 0.71; 98.4% CI 0.59 to 0.86; p<0.0001) for nivolumab plus chemotherapy (14.4 months; 95% CI 13.1 to 16.2) vs. 11.1 months (95% CI 10.0 to 12.1) for chemotherapy alone.

SPS commentary:

Nivolumab plus chemotherapy also showed significant progression-free survival (PFS) benefit vs. chemotherapy alone. Median PFS (HR 0.68; 98% CI: 0.56 to 0.81; p<0.0001) was 7.7 months (95% CI: 7.0 to 9.2) in those treated with nivolumab plus chemotherapy and 6.0 months (95% CI: 5.6 to 6.9) among those treated with chemotherapy alone.

Biospace Inc.